Free Trial
NASDAQ:CRDL

Cardiol Therapeutics Q2 2023 Earnings Report

Cardiol Therapeutics logo
$1.17 0.00 (0.00%)
Closing price 08/22/2025 04:00 PM Eastern
Extended Trading
$1.17 0.00 (-0.09%)
As of 08/22/2025 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cardiol Therapeutics EPS Results

Actual EPS
-$0.09
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Cardiol Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Cardiol Therapeutics Announcement Details

Quarter
Q2 2023
Time
N/A
Conference Call Date
Thursday, August 10, 2023
Conference Call Time
11:00AM ET

Earnings Documents

Cardiol Therapeutics Earnings Headlines

What is HC Wainwright's Estimate for CRDL FY2028 Earnings?
The Top 10 AI Stocks You Need to Know
Discover the 10 Best AI Stocks to Buy Now! The AI revolution is reshaping the investment landscape, and knowing where to place your bets is crucial. Our free report reveals the 10 top AI stocks that should be on your radar right now. Don't miss your chance to get in on these high-potential tech plays.tc pixel
Cardiol Therapeutics Analyst Ratings
Cardiol Therapeutics Analyst Ratings
See More Cardiol Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Cardiol Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cardiol Therapeutics and other key companies, straight to your email.

About Cardiol Therapeutics

Cardiol Therapeutics (NASDAQ:CRDL), a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.

View Cardiol Therapeutics Profile

More Earnings Resources from MarketBeat